Latest Hotspot

Semi-Annual Leqvio® Boosts Statin Efficacy in Lowering Cholesterol in Real-World Care

8 April 2024
3 min read

Novartis has revealed fresh findings indicating that integrating Leqvio (inclisiran) administration biannually into an established regimen of statins, taken to the highest bearable extent and before incorporating ezetimibe as suggested in clinical guidelines, leads to a considerable decrease in low-density lipoprotein (LDL) cholesterol levels. This effect was observed in a practical clinical environment among individuals suffering from atherosclerotic cardiovascular diseases (ASCVD). The data particularly highlighted its efficacy for patients with prior ASCVD incidents who were unable to achieve their targeted LDL cholesterol levels with only statins.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The recently disclosed findings were showcased at the prestigious 2024 gathering of the American College of Cardiology's Annual Scientific Session & Expo, with simultaneous publication in the esteemed Journal of the American College of Cardiology.

"Through V-INITIATE, we examined a strategy for addressing the prevalent issue in clinical carenumerous ASCVD patients not attaining their recommended LDL-C targets with statins alone and the significant underuse of potent non-statin options," stated Dr. Michael Koren, the study's lead researcher, who serves as Medical Director and CEO at Jacksonville Center for Clinical Research.

With an imperative to intensify LDL-C management, V-INITIATE's findings indicate that introducing proven non-statin alternatives such as Leqvio earlier in the treatment process can dramatically lower LDL-C levels for ASCVD patients struggling to achieve or maintain targeted levels, Koren further remarked.

The safety outcomes from the V-INITIATE research were in harmony with those of the pivotal Phase III clinical trials and the ongoing open-label extension studies, ORION-3 and ORION-8, confirming the enduring safety profile of up to six years of treatment.

Dr. David Soergel, Novartis' Global Head of Cardiovascular, Renal and Metabolic Drug Development, noted, V-INITIATE's data stand as a testament to the benefits of commencing novel non-statin treatments like Leqvio early on for ASCVD patients, which could enhance how we manage LDL-C reduction. This research complements the VictORION program's extensive evidence base by supplying real-world insights about Leqvio, a biannual HCP-administered treatment, and underscores its substantial clinical value.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of April 8, 2024, there are 101 investigational drugs for the PCSK9 target, including 56 indications, 122 R&D institutions involved, with related clinical trials reaching 594, and as many as 7746 patents.

Inclisiran is a small interfering RNA drug that targets PCSK9, a protein involved in cholesterol metabolism. As Inclisiran continues to gain regulatory approvals and enters the market, it has the potential to make a significant impact on the management of hypercholesterolemia and associated conditions. Its orphan drug status highlights its potential to address unmet medical needs in specific patient populations. Further research and real-world evidence will be crucial in assessing the long-term efficacy and safety profile of Inclisiran, as well as its potential benefits in various therapeutic areas beyond cardiovascular diseases.

图形用户界面, 文本, 应用程序

描述已自动生成

What is Herbal Medicine Preparation?
"What" Series
2 min read
What is Herbal Medicine Preparation?
8 April 2024
Herbal medicine preparation refers to the process of transforming plant materials—such as leaves, flowers, seeds, roots, and bark—into forms that can be used for therapeutic purposes.
Read →
Ocugen Announces Positive DSMB Review and Begins Recruiting for Mid-Dose OCU410 Trial in Early Geographic Atrophy Study
Latest Hotspot
3 min read
Ocugen Announces Positive DSMB Review and Begins Recruiting for Mid-Dose OCU410 Trial in Early Geographic Atrophy Study
8 April 2024
Ocugen Reports Encouraging Results and DSMB Assessment, Launches Participant Recruitment for Intermediate Dosage Trial of OCU410, a Genetic Treatment Option, in Early-Stage ArMaDa Research Targeting Geographic Atrophy.
Read →
What is Microparticle Technology?
"What" Series
2 min read
What is Microparticle Technology?
8 April 2024
Microparticle technology refers to the creation and application of tiny particles with diameters ranging from a few nanometers to a few micrometers.
Read →
Cidara Therapeutics Showcases New Findings on Innovative Drug-Fc Fusion Molecules at AACR's 2024 Meeting
Latest Hotspot
3 min read
Cidara Therapeutics Showcases New Findings on Innovative Drug-Fc Fusion Molecules at AACR's 2024 Meeting
8 April 2024
Cidara Therapeutics uses its Cloudbreak technology to develop novel drug-Fc conjugates. The company will showcase four posters at the AACR Annual Meeting.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.